2022-01-03Conduct of a clinical study phase II PRI-002 (PRInnovation GmbH)
In Q2 2023, PRInnovation GmbH will conduct a phase II proof-of-concept study under the technical supervision of Priavoid GmbH. The trial will be a randomized, double-blinded, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with mild cognitive impairment to mild dementia due to Alzheimer's disease (AD).
Ansicht der Beschaffung »